Mumbai, India, and Naples, Florida, U.S., October 8, 2026
Lupin Limited, a global pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL, in a single-dose prefilled syringe. The approval strengthens Lupin’s portfolio of generic medicines in the United States and expands its presence in treatments related to vitamin K deficiency and blood-clotting disorders. The FDA determined that Lupin’s product is bioequivalent to the reference listed drug manufactured by International Medication Systems, Limited. Phytonadione Injectable Emulsion is indicated for the treatment and prevention of hypoprothrombinemia, a condition involving reduced blood-clotting ability, and vitamin K deficiency. According to data cited by Lupin from IQVIA, the product had estimated annual U.S. sales of $52.3 million as of August 2026. The approval represents another addition to the company’s U.S. generic medicines portfolio.
FDA Approves Lupin’s Phytonadione Injectable Emulsion
The FDA approval covers Lupin’s Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL, supplied in a single-dose prefilled syringe. The product received approval through the ANDA pathway, which allows generic drug manufacturers to demonstrate that their products meet applicable regulatory requirements, including bioequivalence to an approved reference medicine. The approved product is bioequivalent to the reference listed drug, Phytonadione Injectable Emulsion, 1 mg/0.5 mL, manufactured by International Medication Systems, Limited. Bioequivalence means that the generic product demonstrates comparable availability of the active ingredient in the body under the conditions specified by the relevant regulatory assessment. This helps establish that an approved generic medicine can be expected to perform similarly to its reference product when used according to its labeling. The approval adds another injectable medicine to Lupin’s U.S. portfolio and reflects the company’s continued focus on expanding access to established treatments through generic pharmaceutical development. The product’s single-dose prefilled syringe presentation also provides a ready-to-use format for appropriate clinical settings, subject to the product’s approved labeling and administration requirements.
Phytonadione Supports Vitamin K and Blood-Clotting Care
Phytonadione, also known as vitamin K1, plays an important role in the production of several proteins required for normal blood coagulation. When vitamin K levels are inadequate or clotting activity is impaired, patients may develop hypoprothrombinemia, a condition associated with reduced levels or activity of prothrombin, a protein involved in blood clot formation. Phytonadione Injectable Emulsion is indicated for the treatment and prophylaxis of hypoprothrombinemia and vitamin K deficiency. Its clinical use depends on the underlying cause of the condition and the approved product labeling. Healthcare professionals determine the appropriate treatment based on the patient’s clinical circumstances. The availability of an additional FDA-approved generic product can support competition in the U.S. pharmaceutical market. Generic medicines can provide additional purchasing options for healthcare providers and health systems while maintaining the quality, safety and efficacy standards required for FDA approval. However, the approval announcement does not independently establish the product’s current distribution, launch timing or availability at individual healthcare facilities.
Advertisement
Lupin Strengthens Its U.S. Generic Medicines Portfolio
The phytonadione approval adds to Lupin’s broad portfolio of generic and specialty medicines. Headquartered in Mumbai, India, the company operates across multiple international markets, with products distributed in more than 100 markets. Its portfolio includes generic medicines, complex generics, specialty treatments and biosimilars across several therapeutic areas. According to IQVIA data for the 12 months ending August 2026, the U.S. market for Phytonadione Injectable Emulsion had estimated annual sales of $52.3 million. This figure provides an indication of the market size for the product but does not represent Lupin’s expected revenue or market share following approval. For pharmaceutical manufacturers, securing ANDA approvals is an important part of expanding generic portfolios and competing in established medicine categories. Regulatory approval allows a company to market a product in accordance with the authorization and applicable requirements, while commercial performance depends on factors such as launch timing, pricing, competition and distribution. Lupin’s latest FDA approval highlights its ongoing efforts to broaden its U.S. generic medicine offerings. The authorization of Phytonadione Injectable Emulsion USP provides another option in a market serving patients who require treatment for vitamin K deficiency and related clotting disorders.
Source: Lupin Limited press release
